Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Newsroom
At Memorial Sloan Kettering Cancer Center, our world-renowned cancer researchers, oncologists, clinicians, and scientists are constantly advancing our knowledge about cancer. Our discoveries are improving treatment and care for patients here and all over the world. On this page, you will find news & information about our latest groundbreaking cancer science, exceptional patient care and the dedicated professionals who make it all happen.
For Journalists
Connect with us to reach MSK experts for media inquiries and for story ideas.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.
Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.
Memorial Sloan Kettering Cancer Center (MSK) will award three influential cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the understanding of cancer or are improving the treatment of the disease.
Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has been elected to the National Academy of Medicine (NAM), one of the most prestigious honors in the fields of health and medicine.
Memorial Sloan Kettering Cancer Center (MSK) announced today that Ross Levine, MD, has been named MSK’s new Chief Scientific Officer (CSO). A renowned physician-scientist, Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital (MH) and holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes at MSK.
After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.
Learn how MSK experts are improving the detection and treatment of lung cancer, from fundamental questions of the disease biology to new screening and therapy options.
Metastasis is responsible for about 9 of every 10 cancer deaths, and it remains one of the most daunting and least understood aspects of the disease. Researchers across MSK are approaching a wide variety of metastatic cancer types from many directions.
Cancer Straight Talk brings together national experts and cancer patients to have straightforward, evidence-based conversations. Its mission is to educate and empower cancer patients and their families to make the right decisions and live happier, healthier lives.
